title: Inhaled beta-2 agonist salbutamol for the treatment of transient tachypnea of the newborn.
abstract: OBJECTIVE
  To evaluate the efficacy of inhaled salbutamol, a beta-2 adrenergic agonist, for the treatment of transient tachypnea of the newborn (TTN) and to determine whether inhaled salbutamol is safe in newborn infants.
  
  
  METHODS
  Inhaled salbutamol or normal saline solution was administered to 54 infants with gestational ages ranging from 34 to 39 weeks and TTN. The response to salbutamol therapy was evaluated by determining respiratory rate, clinical score of TTN, level of respiratory support, and fraction of inspired oxygen before and at 30 minutes and 1 and 4 hours after salbutamol nebulization.
  
  
  RESULTS
  Among the 54 infants with TTN, 32 received salbutamol and 22 received normal saline solution. After one dose, the salbutamol group showed significant improvements in respiratory rate, clinical score of TTN, fraction of inspired oxygen, and level of respiratory support (P < .05). After treatment, the mean pH, partial pressure of arterial oxygen, and partial pressure of arterial carbon dioxide values were better in the salbutamol group when compared with the placebo group (P < .05). Duration of hospitalization in the neonatal intensive care unit was also shorter for the salbutamol group (P < .05).
  
  
  CONCLUSIONS
  Inhaled salbutamol treatment was effective with respect to both clinical and laboratory findings of TTN and without adverse events.
authors.affiliation: Department of Pediatrics, Faculty of Medicine, Hacettepe University, Ankara, Turkey. darmangil@gmail.com
authors.forename: Didem
authors.initials: D
authors.lastname: Armangil
authors.forename: Murat
authors.initials: M
authors.lastname: Yurdakök
authors.forename: Ayşe
authors.initials: A
authors.lastname: Korkmaz
authors.forename: Sule
authors.initials: S
authors.lastname: Yiğit
authors.forename: Gülsevin
authors.initials: G
authors.lastname: Tekinalp
mesh_terms: D058666:Adrenergic beta-2 Receptor Agonists / Q000627:therapeutic use*; D000420:Albuterol / Q000627:therapeutic use*; D002245:Carbon Dioxide / Q000097:blood; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007231:Infant, Newborn; D007902:Length of Stay / Q000706:statistics & numerical data; D008297:Male; D009330:Nebulizers and Vaporizers; D010100:Oxygen / Q000097:blood; D010102:Oxygen Inhalation Therapy; D010313:Partial Pressure; D012120:Respiration Disorders / Q000188:drug therapy*; D056152:Respiratory Rate; D012720:Severity of Illness Index
chemical_list: D058666:Adrenergic beta-2 Receptor Agonists; D002245:Carbon Dioxide; D000420:Albuterol; D010100:Oxygen